Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GSD CVE:LTY NYSEARCA:QPT TSE:RVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGSDGlobal System Dynamics$11.11$11.16$9.90▼$11.98$36.77MN/A7,280 shs2 shsLTYLiberty BiopharmaC$2.00+∞C$2.00C$0.06▼C$2.74C$21.54MN/A23,286 shs700 shsQPTAdvisorShares Q Portfolio Blended Allocation ETF$19.10+0.1%$19.10$18.63▼$27.54$1.91MN/A1,912 shs19,400 shsRVXResverlogixC$0.10-9.1%C$0.09C$0.04▼C$0.30C$19.79M0.71113,631 shs321,791 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGSDGlobal System Dynamics0.00%0.00%0.00%0.00%0.00%LTYLiberty Biopharma0.00%0.00%0.00%0.00%0.00%QPTAdvisorShares Q Portfolio Blended Allocation ETF0.00%0.00%0.00%0.00%0.00%RVXResverlogix-2.22%-4.35%-29.03%+175.00%+37.50%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGSDGlobal System DynamicsN/AN/AN/AN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGSDGlobal System Dynamics 0.00N/AN/AN/ALTYLiberty Biopharma 0.00N/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETF 0.00N/AN/AN/ARVXResverlogix 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGSDGlobal System DynamicsN/AN/AN/AN/A($1.84) per shareN/ALTYLiberty BiopharmaN/AN/AC$0.00 per share2,000.00C$0.79 per shareN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AC$0.00 per share132.50C($0.23) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGSDGlobal System Dynamics-$790KN/A0.00∞N/AN/AN/A-2.30%N/ALTYLiberty BiopharmaN/A-C$0.16N/A∞N/AN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/A0.00∞N/AN/AN/AN/AN/ARVXResverlogix-C$2.81M-C$0.02N/A∞N/AN/A6.06%-34.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGSDGlobal System DynamicsN/AN/AN/AN/AN/ALTYLiberty BiopharmaN/AN/AN/AN/AN/AQPTAdvisorShares Q Portfolio Blended Allocation ETF$0.080.42%N/AN/AN/ARVXResverlogixN/A7.02%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGSDGlobal System DynamicsN/A0.010.01LTYLiberty Biopharma8.190.120.12QPTAdvisorShares Q Portfolio Blended Allocation ETFN/AN/AN/ARVXResverlogix-10.950.130.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGSDGlobal System Dynamics24.82%LTYLiberty BiopharmaN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/ARVXResverlogixN/AInsider OwnershipCompanyInsider OwnershipGSDGlobal System Dynamics62.81%LTYLiberty BiopharmaN/AQPTAdvisorShares Q Portfolio Blended Allocation ETFN/ARVXResverlogix42.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGSDGlobal System DynamicsN/A3.31 million1.23 millionNot OptionableLTYLiberty BiopharmaN/A10.77 millionN/ANot OptionableQPTAdvisorShares Q Portfolio Blended Allocation ETFN/A100,000N/ANot OptionableRVXResverlogix19197.94 millionN/ANot OptionableQPT, GSD, RVX, and LTY HeadlinesRecent News About These CompaniesResverlogix Corp.: Resverlogix Announces Voting Results from the 2025 Meeting of ShareholdersJune 30, 2025 | finanznachrichten.deResverlogix Announces Voting Results from the 2025 Meeting of ShareholdersJune 30, 2025 | finance.yahoo.comNew beanless 'coffee' emerges but does it taste any good?September 17, 2024 | bbc.comBNumerous Independent Groups Presented Data that Supports Apabetalone’s Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024September 3, 2024 | msn.comResverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)September 3, 2024 | theglobeandmail.comResverlogix Corp. (RVXCF)July 31, 2024 | finance.yahoo.comResverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture ExtensionJuly 31, 2024 | finance.yahoo.comClosing Bell: Resverlogix Corp up on Tuesday (RVX)July 28, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Wednesday (RVX)July 25, 2024 | theglobeandmail.comResverlogix Announces Updated Annual and Special Meeting of ShareholdersMay 28, 2024 | finance.yahoo.comResverlogix Corp. (RVX.TO)May 16, 2024 | finance.yahoo.comResverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion PrivilegesMay 13, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsJanuary 11, 2024 | finance.yahoo.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)January 4, 2024 | theglobeandmail.comResverlogix Corp. (RVX) Earnings Dates & ReportsDecember 19, 2023 | investing.comResverlogix Corp RVXCFNovember 18, 2023 | morningstar.comMResverlogix Corp RVXNovember 1, 2023 | morningstar.comMResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)October 18, 2023 | theglobeandmail.comResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeQPT, GSD, RVX, and LTY Company DescriptionsGlobal System Dynamics NASDAQ:GSDGlobal System Dynamics, Inc. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company focuses its search on the farming and national security sectors, including farming related operations and businesses that support the farming industry. The company was formerly known as Gladstone Acquisition Corporation. Global System Dynamics, Inc. was incorporated in 2021 and is based in Houston, Texas.Liberty Biopharma CVE:LTYC$2.00 +2.00 (+∞) As of 10/10/2018Liberty Biopharma Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of an automated bioprocessing and cell isolation technology. Its technology is used in the isolation of regenerative cells from human adipose tissues for use in research, cosmetic and aesthetic medicine, burn management, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, and hepatic disease and kidney disease. The company was formerly known as Avagenesis Corp. and changed its name to Liberty Biopharma Inc. in January 2017. Liberty Biopharma Inc. is based in Richmond, Canada.AdvisorShares Q Portfolio Blended Allocation ETF NYSEARCA:QPT$19.10 +0.01 (+0.05%) As of 10/28/2022Resverlogix TSE:RVXC$0.10 -0.01 (-9.09%) As of 04:29 PM EasternResverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Robotics Stocks at the Heart of the Robotics Revolution Analog Devices and an AI-Driven Semiconductor Supercycle Palantir is Selling Off, BigBear.ai Could Be Your Hedge ASML Has Entered Buy Territory, But Only For Patient Investors Lowe’s Builds Value for Investors: Still a Good Buy in 2025 Target: Missing the Mark in 2025—Downtrend May Continue Toll Brothers: A Great Buy and Hold Stock With Risks in 2025 Amazon Stock Sets Up for Breakout After Bullish Crossover Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access